Susquehanna International Group
ZNTL icon

Susquehanna International Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Susquehanna International Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Buy
+45,300
New +$117K ﹤0.01% 12308
2025
Q4 		– Sell
-10,400
Closed -$15.7K – 13814
2025
Q3 		$15.7K Buy
+10,400
New +$15.6K ﹤0.01% 12073
2025
Q2 		– Sell
-30,900
Closed -$49.1K – 13869
2025
Q1 		$49.1K Buy
30,900
+16,100
+109% +$34.7K ﹤0.01% 11872
2024
Q4 		$44.8K Sell
14,800
-18,200
-55% -$59.6K ﹤0.01% 11722
2024
Q3 		$121K Buy
+33,000
New +$120K ﹤0.01% 10912
2024
Q1 		– Sell
-30,200
Closed -$458K – 13530
2023
Q4 		$458K Buy
30,200
+12,800
+74% +$187K ﹤0.01% 8893
2023
Q3 		$349K Sell
17,400
-18,500
-52% -$470K ﹤0.01% 9030
2023
Q2 		$1.01M Buy
+35,900
New +$861K ﹤0.01% 6647
2021
Q3 		– Sell
-12,500
Closed -$665K – 13717
2021
Q2 		$665K Buy
+12,500
New +$669K ﹤0.01% 8871

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Susquehanna International Group's ZNTL Position: Q1 2026 in Review

Susquehanna International Group increased its Zentalis Pharmaceuticals (ZNTL) stake by 5,423% in Q1 2026, buying an estimated $1.45M and bringing the position to 571,257 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #7172.

Susquehanna International Group first reported a position in ZNTL in Q4 2020 and has held it in 22 quarters since. The position peaked at $3.22M in Q3 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

  • Susquehanna International Group held 571,257 shares of Zentalis Pharmaceuticals worth $1.34M as of Q1 2026.
  • Susquehanna International Group bought 560,914 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $1.45M.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7172 holding.
  • Susquehanna International Group first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Susquehanna International Group's Zentalis Pharmaceuticals position peaked at $3.22M in Q3 2021.
  • 102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.